Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among analysts that have covered the stock in the last year is $46.1667.

Several equities analysts have commented on TVRD shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th. HC Wainwright started coverage on shares of Tvardi Therapeutics in a research note on Monday. They set a “buy” rating and a $9.00 target price on the stock. BTIG Research reissued a “buy” rating and set a $15.00 target price on shares of Tvardi Therapeutics in a research note on Wednesday, April 1st. Finally, Wall Street Zen cut shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th.

Hedge Funds Weigh In On Tvardi Therapeutics

Large investors have recently made changes to their positions in the business. Jane Street Group LLC bought a new position in shares of Tvardi Therapeutics during the 4th quarter valued at about $204,000. Goldman Sachs Group Inc. boosted its position in shares of Tvardi Therapeutics by 37.9% during the 4th quarter. Goldman Sachs Group Inc. now owns 33,131 shares of the company’s stock valued at $142,000 after purchasing an additional 9,102 shares in the last quarter. New York State Common Retirement Fund bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $92,000. Quadrature Capital Ltd bought a new position in shares of Tvardi Therapeutics during the 4th quarter valued at about $90,000. Finally, Headlands Technologies LLC bought a new position in shares of Tvardi Therapeutics during the 2nd quarter valued at about $80,000. Institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Trading Down 2.5%

Tvardi Therapeutics stock opened at $2.78 on Wednesday. The stock has a market cap of $26.08 million, a price-to-earnings ratio of -0.90 and a beta of 0.33. The company’s 50-day moving average price is $3.34 and its two-hundred day moving average price is $3.77. Tvardi Therapeutics has a 52 week low of $2.75 and a 52 week high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last released its earnings results on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.08). Research analysts expect that Tvardi Therapeutics will post -2.1 earnings per share for the current fiscal year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.